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a b s t r a c t
Ethnopharmacological relevance: The genus Inula comprises more than one hundred species widespread in
temperate regions of Europe and Asia. Uses of this genus as herbal medicines have been ﬁrst recorded by the
Greek and Roman ancient physicians. In the Chinese Pharmacopoeia, from the 20 Inula spp. distributed in
China, three are used as Traditional Chinese medicines, named Tumuxiang, Xuanfuhua and Jinfeicao. These
medicines are used as expectorants, antitussives, diaphoretics, antiemetics, and bactericides. Moreover, Inula
helenium L. which is mentioned in Minoan, Mycenaean, Egyptian/Assyrian pharmacotherapy and Chilandar
Medical Codex, is good to treat neoplasm, wound, freckles and dandruff. Many other Inula spp. are used in
Ayurvedic and Tibetan traditional medicinal systems for the treatment of diseases such as bronchitis,
diabetes, fever, hypertension and several types of inﬂammation. This review is a critical evaluation of the
published data on the more relevant ethnopharmacological and medicinal uses of Inula spp. and on their
metabolites biological activities. This study allows the identiﬁcation of the ethnopharmacological knowledge
of this genus and will provide insight into the emerging pharmacological applications of Inula spp. facilitating
the prioritirization of future investigations. The corroboration of the ethnopharmacological applications
described in the literature with proved biological activities of Inula spp. secondary metabolites will also be
explored.
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Abbreviations: A-549, human lung carcinoma cell line; ABTS, 2,20-azinobis(3-ethylbenzothiazoline-6-sulfonic acid); AGS, human gastric carcinoma cell line; AHR, airway
hiper-responsiveness; AKT, serine/threonine-speciﬁc protein kinase; AMPK, adenosine 50-monophosphate-activated protein kinase; ATPase, adenosine triphosphatase; B16,
murine melanoma cell line; Bcl-2, apoptosis regulator proteins encoded by the BCL2 gene; Capan-2, human pancreas adenocarcinoma cell line; CC50, 50% cytotoxic
concentration; c-FLIP, cellular FLICE (FADD-like interleukine-1β-converting enzyme) inhibitory protein; COX, cyclooxygenase; COX-1, cyclooxygenase-1; COX-2,
cyclooxygenase-2; CVB3, coxsackievirus B3 enterovirus; DNA, deoxyribonucleic acid; DOX, doxorubicin; DPPH, 1,1-diphenyl-2-picrylhydrazyl radical; ED50, effective dose to
produce effect in 50% of a population; G1, astrocytoma cell line; G2/M, cell cycle checkpoint in eukaryotic organisms; GMK, green monkey kidney cell line; GSTs, glutathione-
S-transferase; HCT-116, colon carcinoma cell line; HeLa, human cervix cancer cell line; HepG-2, liver hepatocellular carcinoma cell line; HIV/AIDS, human immunodeﬁciency
virus infection/acquired immunodeﬁciency syndrome; HIV-1, human immunodeﬁciency virus type 1; HL-60, human promyelocytic leukemia cell line; HSP70, heat shock
protein 70; HSV-1, herpes Simplex Virus type 1; HT-29, human colon adenocarcinoma grade II cell line; IC50, inhibitory concentration for 50% of viability; ICAM-1,
intracellular adhesion molecule-1; IKK, IκB kinase; IKKβ, IκB kinase β; IL-2, Interleukin 2; iNOS, inducible nitric oxide synthase; JNK, c-jun terminal-NH2 kinase; KB, human
nasopharyngeal carcinoma; L6, rat skeletal myoblasts cell line; L929, murine aneuploid ﬁbrosarcoma cell line; L929sA, murine ﬁbrosarcoma cell line; L-NAME, Nω-nitro-L-
arginine methyl ester; LOVO, human colon adenocarcinoma cell line; LPS, lipopolysaccharide; LTB4, leukotriene B4; MBC, minimum bactericidal concentrations; MCF-7,
breast cancer cell line; MDA-MB-435, human breast adenocarcinoma cells; MDCK, madin-Darby canine kidney cell line; MGC-803, human gastric carcinoma cell line; MIC,
minimum inhibitory concentrations; MMP-9, matrix metalloproteinase-9; MRSA, methicillin resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus
aureus; NCI, national Cancer Institute; NF-κB, nuclear factor kappa B; Nrf2, nuclear factor 2-related factor 2; OPN, osteopontin; p47phox, 47-kilodalton cytosolic subunit of
the multi-protein complex known as NADPH oxidase; PAF, platelet-activating factor; PBMCs, human peripheral blood mononuclear cells; PC-3, human prostate cancer cell
lines; PDGF, platelet-derived growth factor; PGE2, prostaglandin E2; PI3K, phosphatidylinositol 3-kinase; PLA2, phospholipase A2; PMA, phorbol myristate acetate; PMNs,
polymorphonuclear leukocytes; PPARγ2, peroxisome proliferator-activated receptor γ 2; QR, quinone reductase; RAW264, murine monocyte/macrophage line derived from
ascitic tumour induced with Abelson leukaemai virus; ROS, reactive oxygen species; SCF, stem cell factor; SGC-7901, gastric cancer cell line; SiHa, human cervix uteri cancer
cell line; SK-28, human melanoma cell line; SOD, superoxide dismutase; sPLA2, secretory phospholipase A2; STAT1, signal transducer and activator of transcription 1;
SW620, human colon carcinoma cell line; Th2, T helper cells type 2; TNFR1, tumour necrosis factor receptor 1; TNF-α, tumour necrosis factor-alpha; TPA, 12-O-
tetradecanoylphorbol-13-acetate; Tyrp1, tyrosinase-related protein 1; U937, human monoblastic leukemia cell line; VCAM-1, vascular adhesion molecule-1; Vero, African
green monkey kidney cell line; VSMCs, vascular smooth muscle cells
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Materials and methods: The major scientiﬁc databases including ScienceDirect, Medline, Scopus and Web of
Sciencewere queried for information on the genus Inula using various keyword combinations, more than 180
papers and patents related to the genus Inula were consulted. The International Plant Name Index was also
used to conﬁrm the species names.
Results: Although the beneﬁts of Inula spp. are known for centuries, there are insufﬁcient scientiﬁc studies to
certify it. Most of the patents are registered by Chinese researchers, proving the traditional use of these plants
in their country. Although a total of sixteen Inula species were reported in the literature to have
ethnopharmacological applications, the species Inula cappa (Buch.-Ham. ex D.Don) DC., Inula racemosa Hook.
f., Inula viscosa (L.) Aiton [actually the accepted name is Dittrichia viscosa (L.) Greuter], Inula helenium, Inula
britannica L. and Inula japonica Thunb. are the most frequently cited ones since their ethnopharmacological
applications are vast. They are used to treat a large spectrum of disorders, mainly respiratory, digestive,
inﬂammatory, dermatological, cancer andmicrobial diseases. Fifteen Inula spp. crude extracts were investigated
and showed interesting biological activities. From these, only 7 involved extracts of the reported spp. used in
traditional medicine and 6 of these were studied to isolate the bioactive compounds. Furthermore, 90 bioactive
compounds were isolated from 16 Inula spp. The characteristic compounds of the genus, sesquiterpene
lactones, are involved in a network of biological effects, and in consequence, the majority of the experimental
studies are focused on these products, especially on their cytotoxic and anti-inﬂammatory activities. The review
shows the chemical composition of the genus Inula and presents the pharmacological effects proved by in vitro
and in vivo experiments, namely the cytotoxic, anti-inﬂammatory (with focus on nitric oxide, arachidonic acid
and NF-κB pathways), antimicrobial, antidiabetic and insecticidal activities.
Conclusions: Although there are ca. 100 species in the genus Inula, only a few species have been investigated so
far. Eight of the sixteen Inula spp. with ethnopharmacological application had been subjected to biological
evaluations and/or phytochemical studies. Despite Inula royleana DC. and Inula obtusifolia A. Kerner are being
used in traditional medicine, as far as we are aware, these species were not subjected to phytochemical or
pharmacological studies. The biological activities exhibited by the compounds isolated from Inula spp., mainly
anti-inﬂammatory and cytotoxic, support some of the described ethnopharmacological applications. Sesqui-
terpene lactone derivatives were identiﬁed as themost studied class, being britannilactone derivatives the most
active ones and present high potential as anti-inﬂammatory drugs, although, their pharmacological effects,
dose–response relationship and toxicological investigations to assess potential for acute or chronic adverse
effects should be further investigated. The experimental results are promising, but the precise mechanism of
action, the compound or extract toxicity, and the dose to be administrated for an optimal effect need to be
investigated. Also human trials (some preclinical studies proved to be remarkable) should be further
investigated. The genus Inula comprises species useful not only in medicine but also in other domains which
makes it a high value-added plant.
& 2014 Elsevier Ireland Ltd. All rights reserved.
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